U.S. Roadside Drug Testing Market Growth & Trends
The U.S. roadside drug testing market is anticipated to reach USD 1.62 billion by 2030 and is anticipated to expand at a CAGR of 4.71% from 2024 to 2030. The market for roadside drug testing in the U.S. is experiencing significant growth, driven by the increasing legalization of recreational cannabis and the rise in drug-impaired driving incidents. As states legalize marijuana, law enforcement agencies face new challenges in ensuring road safety. This has led to a surge in demand for advanced roadside drug testing devices that can quickly and accurately detect various substances.
Traditional methods like urine and blood tests are being supplemented by more efficient technologies, such as oral fluid testing, which is non-invasive and provides immediate results. One of the latest developments is the integration of artificial intelligence (AI) into these devices, enhancing their accuracy and reducing human error. Portable breathalyzers that can detect both alcohol and drugs are also becoming more prevalent. Additionally, there is ongoing research into devices that can measure impairment rather than just the presence of drugs, addressing the issue of varying tolerance levels among individuals.
Federal initiatives and funding are further bolstering this market, with the National Highway Traffic Safety Administration (NHTSA) and other agencies investing in the development of more sophisticated testing tools. As the U.S. continues to address the complexities of drug-impaired driving, the market for roadside drug testing is expected to expand, with innovations focusing on improving detection capabilities and ensuring the safety of all road users.
U.S. Roadside Drug Testing Market Report Highlights
- The alcohol segment accounted for the largest revenue share in 2023. Alcohol testing remains dominant in the market due to the long-standing recognition of alcohol impairment as a significant safety concern, the presence of well-defined legal limits, and the widespread use of standardized devices like breathalyzers for accurate and reliable testing.
- The breath segment captured the largest revenue share in 2023. Breath testing is the most commonly used method for detecting alcohol impairment because it is quick, non-invasive, and provides immediate results. Breathalyzers are portable, making them convenient for use by law enforcement officers during roadside checks.
- The highway police segment held the largest revenue share in 2023. These officers are often the first responders at the scene of traffic stops, accidents, and roadside checks, where impaired driving is a significant concern.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Sample
1.2.3. Test Location
1.2.4. State scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Drug
1.2.2. Sample
1.2.3. Test Location
1.2.4. State scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug And Sample outlook
2.2.2. Test location outlook
2.2.3. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Drug And Sample outlook
2.2.2. Test location outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. U.S. Roadside Drug Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increase in fatalities & accidents due to alcohol/substance abuse by drivers
3.2.1.2. Increased routine checking by police forces
3.2.1.3. Rapid growth in illicit substance consumption
3.2.2. Market restraint analysis
3.2.2.1. High cost of testing equipment
3.3. U.S. Roadside Drug Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Opportunity Analysis
3.3.4. Roadside Drug Testing Spending Landscape, by State
3.3.5. Strategic Initiatives Landscape
3.3.6. Regulatory Landscape, by State Considering Current Competition
3.3.7. BY STATE, BY CITY, BY MUNICIPALITY
3.3.8. California
3.3.9. Texas
3.3.10. Florida
3.3.11. New York
3.3.12. Pennsylvania
3.3.13. Illinois
3.3.14. Ohio
3.3.15. Georgia
3.3.16. North Carolina
3.3.16.1. Penetration Index By State
3.3.16.2. Drug Influence Driving Statistics, By State
3.3.16.3. Dre Landscape And Statistics
3.3.16.4. Dre Training Statistics, 2018-2023
3.3.16.5. Number Of Dre By Category By State
3.3.16.6. Dre Qualitative Landscape By State
3.3.16.7. Case Studies, by State
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increase in fatalities & accidents due to alcohol/substance abuse by drivers
3.2.1.2. Increased routine checking by police forces
3.2.1.3. Rapid growth in illicit substance consumption
3.2.2. Market restraint analysis
3.2.2.1. High cost of testing equipment
3.3. U.S. Roadside Drug Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Opportunity Analysis
3.3.4. Roadside Drug Testing Spending Landscape, by State
3.3.5. Strategic Initiatives Landscape
3.3.6. Regulatory Landscape, by State Considering Current Competition
3.3.7. BY STATE, BY CITY, BY MUNICIPALITY
3.3.8. California
3.3.9. Texas
3.3.10. Florida
3.3.11. New York
3.3.12. Pennsylvania
3.3.13. Illinois
3.3.14. Ohio
3.3.15. Georgia
3.3.16. North Carolina
3.3.16.1. Penetration Index By State
3.3.16.2. Drug Influence Driving Statistics, By State
3.3.16.3. Dre Landscape And Statistics
3.3.16.4. Dre Training Statistics, 2018-2023
3.3.16.5. Number Of Dre By Category By State
3.3.16.6. Dre Qualitative Landscape By State
3.3.16.7. Case Studies, by State
Chapter 4. U.S. Roadside Drug Testing Market: Drug Estimates & Trend Analysis
4.1. U.S. Roadside Drug Testing Market: Drug Dashboard
4.2. U.S. Roadside Drug Testing Market: Drug Movement Analysis
4.3. U.S. Roadside Drug Testing Market by Drug, Revenue
4.4. Alcohol
4.4.1. Alcohol market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Cannabis/Marijuana
4.5.1. Cannabis/Marijuana market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cocaine
4.6.1. Cocaine market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Opioids
4.7.1. Amphetamine & Methamphetamine market estimates and forecasts 2018 to 2030 (USD Million)
4.8. LSD
4.8.1. LSD market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
4.2. U.S. Roadside Drug Testing Market: Drug Movement Analysis
4.3. U.S. Roadside Drug Testing Market by Drug, Revenue
4.4. Alcohol
4.4.1. Alcohol market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Cannabis/Marijuana
4.5.1. Cannabis/Marijuana market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cocaine
4.6.1. Cocaine market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Opioids
4.7.1. Amphetamine & Methamphetamine market estimates and forecasts 2018 to 2030 (USD Million)
4.8. LSD
4.8.1. LSD market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Roadside Drug Testing Market: Sample Estimates & Trend Analysis
5.1. U.S. Roadside Drug Testing Market: Sample Dashboard
5.2. U.S. Roadside Drug Testing Market: Sample Movement Analysis
5.3. U.S. Roadside Drug Testing Market by Sample, Revenue
5.4. Saliva
5.4.1. Saliva market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Breath
5.5.1. Breath market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Urine
5.6.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Blood
5.7.1. Blood market estimates and forecasts 2018 to 2030 (USD Million)
5.2. U.S. Roadside Drug Testing Market: Sample Movement Analysis
5.3. U.S. Roadside Drug Testing Market by Sample, Revenue
5.4. Saliva
5.4.1. Saliva market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Breath
5.5.1. Breath market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Urine
5.6.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Blood
5.7.1. Blood market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Roadside Drug Testing Market: Test Location Estimates & Trend Analysis
6.1. U.S. Roadside Drug Testing Market: Test Location Dashboard
6.2. U.S. Roadside Drug Testing Market: Test Location Movement Analysis
6.3. U.S. Roadside Drug Testing Market by Test Location, Revenue
6.4. Highway Police
6.4.1. Highway Police market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Drug Enforcement Agencies
6.5.1. Drug enforcement agencies market estimates and forecasts 2018 to 2030 (USD Million)
6.2. U.S. Roadside Drug Testing Market: Test Location Movement Analysis
6.3. U.S. Roadside Drug Testing Market by Test Location, Revenue
6.4. Highway Police
6.4.1. Highway Police market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Drug Enforcement Agencies
6.5.1. Drug enforcement agencies market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. U.S. Roadside Drug Testing Market: Regional Estimates & Trend Analysis by Drug, Sample, Test Location
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. U.S.
7.4. Alabama
7.4.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.4.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.4.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.5. Alaska
7.5.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.5.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.5.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.6. Arizona
7.6.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.6.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.6.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.7. Arkansas
7.7.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.7.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.7.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.8. California
7.8.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.8.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.8.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.9. Colorado
7.9.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.9.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.9.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.10. Connecticut
7.10.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.10.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.10.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.11. Delaware
7.11.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.11.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.11.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.12. Florida
7.12.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.12.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.12.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.13. Georgia
7.13.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.13.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.13.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.14. Hawaii
7.14.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.14.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.14.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.15. Idaho
7.15.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.15.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.15.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.16. Illinois
7.16.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.16.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.16.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.17. Indiana
7.17.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.17.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.17.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.18. Iowa
7.18.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.18.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.18.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.19. Kansas
7.19.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.19.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.19.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.20. Kentucky
7.20.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.20.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.20.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.21. Louisiana
7.21.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.21.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.21.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.22. Maine
7.22.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.22.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.22.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.23. Maryland
7.23.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.23.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.23.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.24. Massachusetts
7.24.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.24.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.24.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.25. Michigan
7.25.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.25.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.25.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.26. Minnesota
7.26.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.26.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.26.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.27. Mississippi
7.27.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.27.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.27.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.28. Missouri
7.28.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.28.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.28.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.29. Montana
7.29.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.29.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.29.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.30. Nebraska
7.30.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.30.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.30.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.31. Nevada
7.31.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.31.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.31.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.32. New Hampshire
7.32.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.32.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.32.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.33. New Jersey
7.33.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.33.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.33.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.34. New Mexico
7.34.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.34.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.34.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.35. New York
7.35.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.35.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.35.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.36. North Carolina
7.36.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.36.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.36.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.37. North Dakota
7.37.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.37.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.37.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.38. Ohio
7.38.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.38.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.38.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.39. Oklahoma
7.39.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.39.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.39.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.40. Oregon
7.40.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.40.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.40.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.41. Pennsylvania
7.41.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.41.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.41.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.42. Rhode Island
7.42.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.42.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.42.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.43. South Carolina
7.43.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.43.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.43.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.44. South Dakota
7.44.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.44.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.44.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.45. Tennessee
7.45.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.45.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.45.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.46. Texas
7.46.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.46.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.46.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.47. Utah
7.47.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.47.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.47.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.48. Vermont
7.48.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.48.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.48.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.49. Virginia
7.49.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.49.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.49.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.50. Washington
7.50.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.50.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.50.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.51. West Virginia
7.51.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.51.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.51.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.52. Wisconsin
7.52.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.52.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.52.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.53. Wyoming
7.53.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.53.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.53.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. U.S.
7.4. Alabama
7.4.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.4.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.4.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.5. Alaska
7.5.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.5.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.5.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.6. Arizona
7.6.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.6.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.6.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.7. Arkansas
7.7.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.7.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.7.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.8. California
7.8.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.8.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.8.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.9. Colorado
7.9.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.9.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.9.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.10. Connecticut
7.10.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.10.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.10.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.11. Delaware
7.11.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.11.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.11.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.12. Florida
7.12.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.12.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.12.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.13. Georgia
7.13.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.13.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.13.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.14. Hawaii
7.14.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.14.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.14.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.15. Idaho
7.15.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.15.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.15.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.16. Illinois
7.16.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.16.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.16.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.17. Indiana
7.17.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.17.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.17.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.18. Iowa
7.18.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.18.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.18.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.19. Kansas
7.19.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.19.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.19.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.20. Kentucky
7.20.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.20.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.20.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.21. Louisiana
7.21.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.21.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.21.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.22. Maine
7.22.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.22.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.22.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.23. Maryland
7.23.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.23.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.23.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.24. Massachusetts
7.24.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.24.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.24.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.25. Michigan
7.25.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.25.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.25.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.26. Minnesota
7.26.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.26.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.26.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.27. Mississippi
7.27.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.27.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.27.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.28. Missouri
7.28.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.28.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.28.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.29. Montana
7.29.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.29.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.29.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.30. Nebraska
7.30.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.30.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.30.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.31. Nevada
7.31.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.31.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.31.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.32. New Hampshire
7.32.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.32.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.32.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.33. New Jersey
7.33.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.33.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.33.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.34. New Mexico
7.34.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.34.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.34.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.35. New York
7.35.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.35.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.35.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.36. North Carolina
7.36.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.36.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.36.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.37. North Dakota
7.37.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.37.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.37.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.38. Ohio
7.38.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.38.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.38.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.39. Oklahoma
7.39.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.39.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.39.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.40. Oregon
7.40.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.40.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.40.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.41. Pennsylvania
7.41.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.41.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.41.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.42. Rhode Island
7.42.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.42.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.42.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.43. South Carolina
7.43.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.43.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.43.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.44. South Dakota
7.44.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.44.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.44.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.45. Tennessee
7.45.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.45.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.45.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.46. Texas
7.46.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.46.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.46.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.47. Utah
7.47.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.47.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.47.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.48. Vermont
7.48.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.48.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.48.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.49. Virginia
7.49.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.49.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.49.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.50. Washington
7.50.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.50.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.50.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.51. West Virginia
7.51.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.51.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.51.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.52. Wisconsin
7.52.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.52.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.52.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
7.53. Wyoming
7.53.1. Market estimates and forecasts, by drug, 2018 to 2030 (USD Million)
7.53.2. Market estimates and forecasts, by sample, 2018 to 2030 (USD Million)
7.53.3. Market estimates and forecasts, by test location, 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Drägerwerk AG & Co. KGaA
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Abbott
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Intoximeters
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Lifeloc Technologies, Inc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Hound Labs, Inc
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Immunalysis Corporation
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. CMI Inc
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Alcohol Countermeasure Systems Corp
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. AK GlobalTech Corp
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. PAS Systems International, Inc
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Drägerwerk AG & Co. KGaA
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Abbott
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Intoximeters
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Lifeloc Technologies, Inc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Hound Labs, Inc
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Immunalysis Corporation
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. CMI Inc
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Alcohol Countermeasure Systems Corp
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. AK GlobalTech Corp
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. PAS Systems International, Inc
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 U.S. Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 4 U.S. Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 5 U.S. Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 6 Alabama Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 7 Alabama Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 8 Alabama Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 9 Alaska Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 10 Alaska Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 11 Alaska Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 12 Arizona Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 13 Arizona Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 14 Arizona Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 15 Arkansas Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 16 Arkansas Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 17 Arkansas Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 18 California Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 19 California Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 20 California Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 21 Colorado Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 22 Colorado Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 23 Colorado Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 24 Connecticut Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 25 Connecticut Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 26 Connecticut Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 27 Delaware Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 28 Delaware Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 29 Delaware Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 30 Florida Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 31 Florida Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 32 Florida Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 33 Georgia Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 34 Georgia Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 35 Georgia Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 36 Hawaii Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 37 Hawaii Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 38 Hawaii Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 39 Idaho Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 40 Idaho Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 41 Idaho Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 42 Illinois Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 43 Illinois Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 44 Illinois Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 45 Indiana Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 46 Indiana Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 47 Indiana Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 48 Iowa Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 49 Iowa Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 50 Iowa Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 51 Kansas Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 52 Kansas Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 53 Kansas Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 54 Kentucky Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 55 Kentucky Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 56 Kentucky Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 57 Louisiana Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 58 Louisiana Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 59 Louisiana Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 60 Maine Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 61 Maine Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 62 Maine Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 63 Maryland Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 64 Maryland Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 65 Maryland Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 66 Massachusetts Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 67 Massachusetts Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 68 Massachusetts Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 69 Michigan Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 70 Michigan Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 71 Michigan Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 72 Minnesota Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 73 Minnesota Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 74 Minnesota Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 75 Mississippi Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 76 Mississippi Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 77 Mississippi Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 78 Missouri Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 79 Missouri Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 80 Missouri Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 81 Montana Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 82 Montana Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 83 Montana Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 84 Nebraska Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 85 Nebraska Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 86 Nebraska Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 87 Nevada Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 88 Nevada Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 89 Nevada Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 90 New Hampshire Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 91 New Hampshire Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 92 New Hampshire Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 93 New Jersey Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 94 New Jersey Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 95 New Jersey Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 96 New Mexico Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 97 New Mexico Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 98 New Mexico Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 99 New York Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 100 New York Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 101 New York Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 102 North Carolina Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 103 North Carolina Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 104 North Carolina Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 105 North Dakota Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 106 North Dakota Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 107 North Dakota Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 108 Ohio Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 109 Ohio Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 110 Ohio Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 111 Oklahoma Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 112 Oklahoma Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 113 Oklahoma Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 114 Oregon Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 115 Oregon Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 116 Oregon Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 117 Pennsylvania Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 118 Pennsylvania Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 119 Pennsylvania Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 120 Rhode Island Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 121 Rhode Island Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 122 Rhode Island Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 123 South Carolina Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 124 South Carolina Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 125 South Carolina Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 126 South Dakota Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 127 South Dakota Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 128 South Dakota Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 129 Tennessee Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 130 Tennessee Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 131 Tennessee Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 132 Texas Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 133 Texas Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 134 Texas Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 135 Utah Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 136 Utah Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 137 Utah Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 138 Vermont Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 139 Vermont Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 140 Vermont Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 141 Virginia Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 142 Virginia Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 143 Virginia Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 144 Washington Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 145 Washington Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 146 Washington Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 147 West Virginia Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 148 West Virginia Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 149 West Virginia Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 150 Wisconsin Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 151 Wisconsin Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 152 Wisconsin Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 153 Wyoming Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 154 Wyoming Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 155 Wyoming Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 2 List of Abbreviations
Table 3 U.S. Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 4 U.S. Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 5 U.S. Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 6 Alabama Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 7 Alabama Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 8 Alabama Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 9 Alaska Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 10 Alaska Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 11 Alaska Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 12 Arizona Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 13 Arizona Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 14 Arizona Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 15 Arkansas Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 16 Arkansas Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 17 Arkansas Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 18 California Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 19 California Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 20 California Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 21 Colorado Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 22 Colorado Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 23 Colorado Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 24 Connecticut Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 25 Connecticut Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 26 Connecticut Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 27 Delaware Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 28 Delaware Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 29 Delaware Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 30 Florida Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 31 Florida Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 32 Florida Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 33 Georgia Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 34 Georgia Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 35 Georgia Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 36 Hawaii Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 37 Hawaii Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 38 Hawaii Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 39 Idaho Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 40 Idaho Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 41 Idaho Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 42 Illinois Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 43 Illinois Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 44 Illinois Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 45 Indiana Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 46 Indiana Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 47 Indiana Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 48 Iowa Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 49 Iowa Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 50 Iowa Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 51 Kansas Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 52 Kansas Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 53 Kansas Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 54 Kentucky Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 55 Kentucky Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 56 Kentucky Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 57 Louisiana Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 58 Louisiana Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 59 Louisiana Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 60 Maine Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 61 Maine Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 62 Maine Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 63 Maryland Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 64 Maryland Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 65 Maryland Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 66 Massachusetts Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 67 Massachusetts Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 68 Massachusetts Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 69 Michigan Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 70 Michigan Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 71 Michigan Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 72 Minnesota Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 73 Minnesota Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 74 Minnesota Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 75 Mississippi Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 76 Mississippi Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 77 Mississippi Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 78 Missouri Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 79 Missouri Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 80 Missouri Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 81 Montana Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 82 Montana Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 83 Montana Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 84 Nebraska Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 85 Nebraska Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 86 Nebraska Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 87 Nevada Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 88 Nevada Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 89 Nevada Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 90 New Hampshire Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 91 New Hampshire Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 92 New Hampshire Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 93 New Jersey Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 94 New Jersey Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 95 New Jersey Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 96 New Mexico Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 97 New Mexico Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 98 New Mexico Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 99 New York Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 100 New York Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 101 New York Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 102 North Carolina Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 103 North Carolina Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 104 North Carolina Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 105 North Dakota Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 106 North Dakota Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 107 North Dakota Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 108 Ohio Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 109 Ohio Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 110 Ohio Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 111 Oklahoma Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 112 Oklahoma Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 113 Oklahoma Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 114 Oregon Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 115 Oregon Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 116 Oregon Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 117 Pennsylvania Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 118 Pennsylvania Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 119 Pennsylvania Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 120 Rhode Island Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 121 Rhode Island Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 122 Rhode Island Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 123 South Carolina Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 124 South Carolina Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 125 South Carolina Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 126 South Dakota Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 127 South Dakota Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 128 South Dakota Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 129 Tennessee Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 130 Tennessee Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 131 Tennessee Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 132 Texas Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 133 Texas Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 134 Texas Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 135 Utah Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 136 Utah Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 137 Utah Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 138 Vermont Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 139 Vermont Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 140 Vermont Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 141 Virginia Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 142 Virginia Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 143 Virginia Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 144 Washington Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 145 Washington Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 146 Washington Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 147 West Virginia Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 148 West Virginia Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 149 West Virginia Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 150 Wisconsin Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 151 Wisconsin Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 152 Wisconsin Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
Table 153 Wyoming Roadside Drug Testing, by drug, 2018 - 2030 (USD Million)
Table 154 Wyoming Roadside Drug Testing, by sample, 2018 - 2030 (USD Million)
Table 155 Wyoming Roadside Drug Testing, by test location, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 U.S. Roadside Drug Testing Market Segmentation
Fig. 8 Market Snapshot, 2023
Fig. 9 Market Trends & Outlook
Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 U.S. Roadside Drug Testing Market: Drug Movement Analysis
Fig. 16 U.S. Roadside Drug Testing Market, for Alcohol, 2018 - 2030 (USD Million)
Fig. 17 U.S. Roadside Drug Testing Market, for Cannabis/Marijuana, 2018 - 2030 (USD Million)
Fig. 18 U.S. Roadside Drug Testing Market, for Cocaine, 2018 - 2030 (USD Million)
Fig. 19 U.S. Roadside Drug Testing Market, for Opioids, 2018 - 2030 (USD Million)
Fig. 20 U.S. Roadside Drug Testing Market, for Amphetamine & Methamphetamine, 2018 - 2030 (USD Million)
Fig. 21 U.S. Roadside Drug Testing Market, for LSD, 2018 - 2030 (USD Million)
Fig. 22 U.S. Roadside Drug Testing Market, for Others, 2018 - 2030 (USD Million)
Fig. 23 U.S. Roadside Drug Testing Market: Test Location Movement Analysis
Fig. 24 U.S. Roadside Drug Testing Market, for Highway Police, 2018 - 2030 (USD Million)
Fig. 25 U.S. Roadside Drug Testing Market, for Drug Enforcement Agencies, 2018 - 2030 (USD Million)
Fig. 26 U.S. Roadside Drug Testing Market: Sample Movement Analysis
Fig. 27 U.S. Roadside Drug Testing Market, for Saliva, 2018 - 2030 (USD Million)
Fig. 28 U.S. Roadside Drug Testing Market, for Breath, 2018 - 2030 (USD Million)
Fig. 29 U.S. Roadside Drug Testing Market, for Urine, 2018 - 2030 (USD Million)
Fig. 30 U.S. Roadside Drug Testing Market, for Blood, 2018 - 2030 (USD Million)
Fig. 31 U.S. Roadside Drug Testing Market: Region State Analysis
Fig. 32 Alabama U.S. Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 33 Alaska U.S. Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 34 Arizona Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 35 Arkansas Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 36 California Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 37 Colorado Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 38 Connecticut Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 39 Delaware Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 40 Florida Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 41 Georgia Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 42 Hawaii Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 43 Idaho Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 44 Illinois Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 45 Indiana Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 46 Iowa Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 47 Kansas Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 48 Louisiana Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 49 Maine Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 50 Maryland Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 51 Massachusetts Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 52 Michigan Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 53 Minnesota Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 54 Mississippi Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 55 Missouri Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 56 Montana Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 57 Nebraska Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 58 Nevada Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 59 New Hampshire Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 60 New Jersey Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 61 New Mexico Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 62 New York Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 63 North Carolina Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 64 North Dakota Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 65 Ohio Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 66 Oklahoma Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 67 Oregon Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 68 Pennsylvania Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 69 Rhode Island Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 70 South Carolina Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 71 South Dakota Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 72 Tennessee Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 73 Texas Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 74 Utah Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 75 Vermont Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 76 Virginia Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 77 Washington Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 78 West Virginia Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 79 Wisconsin Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 80 Wyoming Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 U.S. Roadside Drug Testing Market Segmentation
Fig. 8 Market Snapshot, 2023
Fig. 9 Market Trends & Outlook
Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 U.S. Roadside Drug Testing Market: Drug Movement Analysis
Fig. 16 U.S. Roadside Drug Testing Market, for Alcohol, 2018 - 2030 (USD Million)
Fig. 17 U.S. Roadside Drug Testing Market, for Cannabis/Marijuana, 2018 - 2030 (USD Million)
Fig. 18 U.S. Roadside Drug Testing Market, for Cocaine, 2018 - 2030 (USD Million)
Fig. 19 U.S. Roadside Drug Testing Market, for Opioids, 2018 - 2030 (USD Million)
Fig. 20 U.S. Roadside Drug Testing Market, for Amphetamine & Methamphetamine, 2018 - 2030 (USD Million)
Fig. 21 U.S. Roadside Drug Testing Market, for LSD, 2018 - 2030 (USD Million)
Fig. 22 U.S. Roadside Drug Testing Market, for Others, 2018 - 2030 (USD Million)
Fig. 23 U.S. Roadside Drug Testing Market: Test Location Movement Analysis
Fig. 24 U.S. Roadside Drug Testing Market, for Highway Police, 2018 - 2030 (USD Million)
Fig. 25 U.S. Roadside Drug Testing Market, for Drug Enforcement Agencies, 2018 - 2030 (USD Million)
Fig. 26 U.S. Roadside Drug Testing Market: Sample Movement Analysis
Fig. 27 U.S. Roadside Drug Testing Market, for Saliva, 2018 - 2030 (USD Million)
Fig. 28 U.S. Roadside Drug Testing Market, for Breath, 2018 - 2030 (USD Million)
Fig. 29 U.S. Roadside Drug Testing Market, for Urine, 2018 - 2030 (USD Million)
Fig. 30 U.S. Roadside Drug Testing Market, for Blood, 2018 - 2030 (USD Million)
Fig. 31 U.S. Roadside Drug Testing Market: Region State Analysis
Fig. 32 Alabama U.S. Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 33 Alaska U.S. Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 34 Arizona Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 35 Arkansas Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 36 California Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 37 Colorado Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 38 Connecticut Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 39 Delaware Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 40 Florida Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 41 Georgia Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 42 Hawaii Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 43 Idaho Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 44 Illinois Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 45 Indiana Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 46 Iowa Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 47 Kansas Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 48 Louisiana Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 49 Maine Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 50 Maryland Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 51 Massachusetts Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 52 Michigan Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 53 Minnesota Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 54 Mississippi Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 55 Missouri Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 56 Montana Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 57 Nebraska Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 58 Nevada Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 59 New Hampshire Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 60 New Jersey Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 61 New Mexico Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 62 New York Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 63 North Carolina Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 64 North Dakota Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 65 Ohio Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 66 Oklahoma Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 67 Oregon Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 68 Pennsylvania Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 69 Rhode Island Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 70 South Carolina Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 71 South Dakota Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 72 Tennessee Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 73 Texas Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 74 Utah Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 75 Vermont Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 76 Virginia Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 77 Washington Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 78 West Virginia Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 79 Wisconsin Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Fig. 80 Wyoming Roadside Drug Testing Market, 2018 - 2030 (USD Million)
Companies Mentioned
- Drägerwerk AG & Co. KGaA
- Abbott.
- Intoximeters
- Lifeloc Technologies, Inc.
- Hound Labs, Inc.
- Immunalysis Corporation
- CMI Inc.
- Alcohol Countermeasure Systems Corp.
- AK GlobalTech Corp.
- PAS Systems International, Inc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 219 |
| Published | August 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 1.17 Billion |
| Forecasted Market Value ( USD | $ 1.62 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | United States |
| No. of Companies Mentioned | 10 |
